RxDoctor Payments Data

Janet Betchkal, MD

Ophthalmology · Jacksonville, FLNPI 1700881976

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (54.2%), food and beverage and education — rather than concentrated in one kind of arrangement. AbbVie accounts for 80.7% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2019 at $1,121 and has fallen 81.4% since, to $209 in 2025. That places this record below the midpoint for ophthalmology clinicians in FL, where the typical reported total is $1,824.

$1,495in general payments, 2019–2025

Across 14 payments — averaging $106.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • NEW World Medical,inc.$129
  • Bausch & Lomb Americas Inc.$82
  • Novartis$76

What the payments were for

  • Consulting fees$81054%
  • Food & beverage$52035%
  • Education$1208%
  • Gifts$453%

General payments by program year

19
20
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)10$1,207
NEW World Medical,inc.1$129
Bausch & Lomb Americas Inc.1$82
Novartis2$76

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,495 in reported general payments places this provider in the 45th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida →

Medicare billing

Part B allowed, 2024
$285,601
Medicare patients
496
Services billed
3,275

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost1,168$583,795
RhopressaNetarsudil Mesylate531$293,435
RestasisCyclosporine86$76,757
Alphagan PBrimonidine Tartrate76$36,130
Travoprost212$33,887
Betaxolol Hcl241$30,674
Dorzolamide Hcl692$15,097
Cyclosporine32$12,582
Betoptic SBetaxolol Hcl26$12,034
Brimonidine Tartrate443$11,116
Prednisolone Acetate114$7,992
Travatan ZTravoprost11$7,282
Brinzolamide36$6,812
Bimatoprost68$4,452
Loteprednol Etabonate15$2,250

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Alphagan P$1,207$696,6821,330 claims
NovartisTravatan Z$76$7,28211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,405 ophthalmology providers in Florida.

Other ophthalmology in Jacksonville

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →